REFERENCES
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a per-sistent public health problem. Clin Microbiol Rev 2007; 20: 133–163.
- Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359–366.
- Canuto MM, Gutierrez Rodero F. Antifungal drug resistance to azole and polyenes. Lancet Infect Dis 2002; 2: 550–563.
- Singh J, Rimel D, Kappe R. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. Mycoses 2006; 49: 96–103.
- Favel A et al Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother 2004; 53: 526–529.
- Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–4431.
- National Committee for Clinical Laboratory Standards. Reference for broth dilution antifungal susceptibility testing of yeasts. Approved Standards M27-A2. 2002. NCCLS, Wayne, PA
- Rex JH, Cooper CR, Merz WG et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906–909.
- Barchiesi F, Maracci M, Baldassarri I, Spreghini E, Giannini D, Scalise G. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. Diagn Microbiol Infect Dis 2004; 50: 179–185.